Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:AVRO

AVROBIO (AVRO) Stock Price, News & Analysis

AVROBIO logo

About AVROBIO Stock (NASDAQ:AVRO)

Key Stats

Today's Range
$1.38
$1.44
50-Day Range
$1.40
$18.24
52-Week Range
$0.88
$1.65
Volume
206,800 shs
Average Volume
269,831 shs
Market Capitalization
$62.85 million
P/E Ratio
2.03
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Receive AVRO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.

AVRO Stock News Headlines

Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
TD Cowen Sticks to Their Buy Rating for Tectonic Therapeutic (TECX)
See More Headlines

AVRO Stock Analysis - Frequently Asked Questions

AVROBIO, Inc. (NASDAQ:AVRO) released its quarterly earnings results on Thursday, November, 4th. The company reported ($9.00) EPS for the quarter, hitting the consensus estimate of ($9.00).

AVROBIO shares reverse split before market open on Thursday, June 20th 2024. The 1-12 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

AVROBIO (AVRO) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities acted as the underwriters for the IPO and Wedbush Securities was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that AVROBIO investors own include Meta Platforms (META), NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Adobe (ADBE).

Company Calendar

Last Earnings
11/04/2021
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:AVRO
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
$12.16 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.13 per share

Miscellaneous

Free Float
40,764,000
Market Cap
$62.85 million
Optionable
Optionable
Beta
1.23
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:AVRO) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners